Gilead prices Covid-19 drug candidate remdesivir at S$3,258 per patient in US

WASHINGTON — Gilead Sciences has priced its Covid-19 drug candidate remdesivir at US$390 (S$543) per vial for the United States and governments of other developed countries, it said on Monday (June 29), setting the price of a five-day course at $2,340 (S$3,258) per patient.

The price for US private insurance companies will be US$520 per vial, the drugmaker said, which equates to a total of US$3,120 per patient.

Experts have suggested that Gilead would need to avoid the appearance of taking advantage of a health crisis for profits.

Wall Street analysts have said the antiviral drug could generate billions of dollars in revenue over the next couple of years if the pandemic continues. REUTERS

Read more at https://www.todayonline.com/world/gilead-prices-covid-19-drug-candidate-remdesivir-s3258-patient-us

 

 

Author: CA Care

In obedience to God's will and counting on His mercies and blessings, and driven by the desire to care for one another, we seek to provide help, direction and relief to those who suffer from cancer.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s